BI 1387446 - Boehringer-Ingelheim
Alternative Names: BI-1387446Latest Information Update: 19 Apr 2024
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics; Small molecules
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Mar 2024 Boehringer Ingelheim completes phase I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) in United Kingdom, USA and Spain (Intratumoural) (NCT04147234)
- 20 Oct 2023 BI 1387446 is still in phase I trials for Solid tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (Intratumoural, Injection)
- 20 Oct 2023 Adverse events data from a phase I trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)